<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04800679</url>
  </required_header>
  <id_info>
    <org_study_id>97378</org_study_id>
    <nct_id>NCT04800679</nct_id>
  </id_info>
  <brief_title>Intravitreal Bevacizumab vs Laser vs Combination of Bevacizumab and Modified Laser in PDR</brief_title>
  <official_title>Combination Therapy for PDR</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shahid Beheshti University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shahid Beheshti University of Medical Sciences</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this randomized 3-armed clinical trial, 105 eyes with PDR will be included and divided&#xD;
      randomly into 3 groups: IVB group (35 eyes) that receive 4 monthly IVB injections and then&#xD;
      rescue IVB, PRP group (35 eyes) that undergo full PRP in 2 or 3 sessions and then rescue IVB,&#xD;
      and combination group (35 eyes) that receive 2 bimonthly IVB injections and a modified laser&#xD;
      (1 session anterior to the equator) and then rescue IVB or laser. Diabetic macular edema&#xD;
      (DME) will be treated independently in all groups by IVB. Primary outcome will be the number&#xD;
      and activity of neovascularizations at 4,8 and 12 months and secondary measures will be&#xD;
      changes in best corrected visual acuity (BCVA) and central macular thickness (CMT), and&#xD;
      number of examinations and injection.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2020</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Actual">July 1, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Extent of neovascular tissues in disc-diameter measured by investigator according to the wide-field FAG</measure>
    <time_frame>12 months</time_frame>
    <description>Number of neovascular tissue counted by investigator according to FAG</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Best corrected visual acuity based on Snellen chart</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Central retinal thickness according to macular OCT</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">105</enrollment>
  <condition>Proliferative Diabetic Retinopathy</condition>
  <arm_group>
    <arm_group_label>intravitreal bevacizumab injections and then rescue</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PRP group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>IVB injections and a modified laser</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>receive 4 monthly IVB injections and then rescue IVB</intervention_name>
    <description>IVB group that receive 4 monthly IVB injections and then rescue IVB</description>
    <arm_group_label>intravitreal bevacizumab injections and then rescue</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PRP group</intervention_name>
    <description>PRP group that undergo full PRP in 2 or 3 sessions and then rescue IVB</description>
    <arm_group_label>PRP group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IVB injections and a modified laser</intervention_name>
    <description>Combination group that receive 2 bimonthly IVB injections and a modified laser (1 session anterior to the equator) and then rescue IVB or laser</description>
    <arm_group_label>IVB injections and a modified laser</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Presence of PDR with the indication of full PRP according the intend of investigator&#xD;
&#xD;
          -  Best corrected visual acuity of 20/320 or better&#xD;
&#xD;
          -  Media clarity, pupillary dilation and patient's cooperation sufficient for full PRP,&#xD;
             wide-field FAG and OCT&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of prior PRP with more than 100 burns outside the posterior pole&#xD;
&#xD;
          -  Tractional retinal detachment involving the macula&#xD;
&#xD;
          -  Evidence of neoplasia of angle on examination&#xD;
&#xD;
          -  Macular edema due to a cause other than DME&#xD;
&#xD;
          -  Any ocular condition which may change visual acuity during the study&#xD;
&#xD;
          -  Substantial cataract which has declined the vision by 3 lines or more&#xD;
&#xD;
          -  History of intravitreal injection of anti-VEGF agent in past 2 months&#xD;
&#xD;
          -  History of any use of corticosteroid during past 4 months&#xD;
&#xD;
          -  History of major intra-ocular surgery except cataract surgery&#xD;
&#xD;
          -  History of YAG laser capsulotomy during past 2 months&#xD;
&#xD;
          -  Aphakia and uncontrolled glaucoma according to investigator judgment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Alireza Ramezani, MD</last_name>
    <phone>009822591616</phone>
    <email>labbafi@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ophthalmic Research Center</name>
      <address>
        <city>Tehran</city>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ali reza Ramezani, MD</last_name>
      <phone>009822591616</phone>
      <email>labbafi@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 28, 2019</study_first_submitted>
  <study_first_submitted_qc>March 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 16, 2021</study_first_posted>
  <last_update_submitted>March 13, 2021</last_update_submitted>
  <last_update_submitted_qc>March 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shahid Beheshti University of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Zahra Rabbani Khah</investigator_full_name>
    <investigator_title>Head of ophthalmic research center</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetic Retinopathy</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

